葡萄牙首次发现产KPC-3碳青霉烯酶的耐黏菌素和替加环素菌株。
First Description of Colistin and Tigecycline-Resistant Producing KPC-3 Carbapenemase in Portugal.
作者信息
Caneiras Cátia, Calisto Filipa, Jorge da Silva Gabriela, Lito Luis, Melo-Cristino José, Duarte Aida
机构信息
Microbiology and Immunology Department, Interdisciplinary Research Centre Egas Moniz (CiiEM), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
Institute of Environmental Health (ISAMB), Faculty of Medicine, Universidade de Lisboa, 1649-028 Lisboa, Portugal.
出版信息
Antibiotics (Basel). 2018 Nov 6;7(4):96. doi: 10.3390/antibiotics7040096.
Abstract
Herein, we describe a case report of carbapenem-resistant and isolates that were identified from the same patient at a Tertiary University Hospital Centre in Portugal. Antimicrobial susceptibility and the molecular characterization of resistance and virulence determinants were performed. PCR screening identified the presence of the resistance genes , and in both isolates. The KPC-3 isolate belonged to the ST-14 high risk clone and accumulated an uncommon resistance and virulence profile additional to a horizontal dissemination capacity. In conclusion, the molecular screening led to the first identification of the KPC-3 producer in Portugal with a full antimicrobial resistance profile including tigecycline and colistin.
摘要
在此，我们描述了在葡萄牙一家三级大学医院中心从同一患者身上鉴定出的耐碳青霉烯类菌株的病例报告。进行了抗菌药物敏感性以及耐药性和毒力决定因素的分子特征分析。PCR筛查确定在两种分离株中均存在耐药基因、和。KPC-3分离株属于ST-14高风险克隆，除具有水平传播能力外，还积累了罕见的耐药和毒力谱。总之，分子筛查首次在葡萄牙鉴定出具有包括替加环素和黏菌素在内的完整抗菌药物耐药谱的KPC-3产生菌。
相似文献
1
First Description of Colistin and Tigecycline-Resistant Producing KPC-3 Carbapenemase in Portugal.
Antibiotics (Basel). 2018 Nov 6;7(4):96. doi: 10.3390/antibiotics7040096.
2
Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
Int J Antimicrob Agents. 2014 Aug;44(2):112-6. doi: 10.1016/j.ijantimicag.2014.04.014. Epub 2014 Jun 2.
3
Molecular characterization of carbapenem-resistant Klebsiella pneumoniae isolates from a university hospital in Brazil.
J Infect Dev Ctries. 2017 Jun 1;11(5):379-386. doi: 10.3855/jidc.8614.
4
Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: Emergence of hypermucoviscous ST25 and high-risk clone ST307.
J Glob Antimicrob Resist. 2019 Sep;18:238-242. doi: 10.1016/j.jgar.2019.06.005. Epub 2019 Jun 13.
5
Molecular identification of tigecycline- and colistin-resistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013.
J Med Microbiol. 2015 Sep;64(9):993-997. doi: 10.1099/jmm.0.000127. Epub 2015 Jul 14.
6
A ten-year surveillance study of carbapenemase-producing Klebsiella pneumoniae in a tertiary care Greek university hospital: predominance of KPC- over VIM- or NDM-producing isolates.
J Med Microbiol. 2016 Mar;65(3):240-246. doi: 10.1099/jmm.0.000217. Epub 2015 Dec 23.
7
Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018.
Int J Antimicrob Agents. 2019 Sep;54(3):318-328. doi: 10.1016/j.ijantimicag.2019.06.009. Epub 2019 Jun 14.
8
Carbapenemase-producing Enterobacteriaceae in a tertiary hospital in Madrid, Spain: high percentage of colistin resistance among VIM-1-producing Klebsiella pneumoniae ST11 isolates.
Int J Antimicrob Agents. 2014 May;43(5):460-4. doi: 10.1016/j.ijantimicag.2014.01.021. Epub 2014 Feb 22.
9
Prevalence and molecular characterization of carbapenemase-producing gram-negative bacteria from a university hospital in China.
Infect Dis (Lond). 2016 Feb;48(2):138-46. doi: 10.3109/23744235.2015.1094822. Epub 2015 Oct 14.
10
Whole genome sequencing for the molecular characterization of carbapenem-resistant Klebsiella pneumoniae strains isolated at the Italian ASST Fatebenefratelli Sacco Hospital, 2012-2014.
BMC Infect Dis. 2017 Oct 10;17(1):666. doi: 10.1186/s12879-017-2760-7.
引用本文的文献
1
Invasive liver abscess syndrome complicated by carbapenem-resistant infection: a case report.
Front Med (Lausanne). 2025 Jan 7;11:1511734. doi: 10.3389/fmed.2024.1511734. eCollection 2024.
2
Tackling Carbapenem Resistance and the Imperative for One Health Strategies-Insights from the Portuguese Perspective.
Antibiotics (Basel). 2024 Jun 14;13(6):557. doi: 10.3390/antibiotics13060557.
3
CRISPR-Based Gene Editing in to Combat Antimicrobial Resistance.
Pharmaceuticals (Basel). 2023 Jun 23;16(7):920. doi: 10.3390/ph16070920.
4
Antimicrobial Resistance in Romania: Updates on Gram-Negative ESCAPE Pathogens in the Clinical, Veterinary, and Aquatic Sectors.
Int J Mol Sci. 2023 Apr 26;24(9):7892. doi: 10.3390/ijms24097892.
5
Penicillin Binding Protein 7/8 Is a Potential Drug Target in Carbapenem-Resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0103322. doi: 10.1128/aac.01033-22. Epub 2022 Dec 7.
6
Evasion of Antimicrobial Activity in by Target Site Modifications: An Effective Resistance Mechanism.
Int J Mol Sci. 2022 Jun 13;23(12):6582. doi: 10.3390/ijms23126582.
7
Whole-Genome Sequencing Enables Molecular Characterization of Non-Clonal Group 258 High-Risk Clones (ST13, ST17, ST147 and ST307) among Carbapenem-Resistant from a Tertiary University Hospital Centre in Portugal.
Microorganisms. 2022 Feb 11;10(2):416. doi: 10.3390/microorganisms10020416.
8
First Outbreak of NDM-1-Producing ST11 in a Portuguese Hospital Centre during the COVID-19 Pandemic.
Microorganisms. 2022 Jan 23;10(2):251. doi: 10.3390/microorganisms10020251.
9
The Gram-Negative Bacilli Isolated from Caves- and and a Review of Their Involvement in Human Infections.
Int J Environ Res Public Health. 2022 Feb 17;19(4):2324. doi: 10.3390/ijerph19042324.
10
Pneumonia: A Rare Cause of Infection in a Patient with COVID-19.
Microorganisms. 2021 Nov 17;9(11):2369. doi: 10.3390/microorganisms9112369.
本文引用的文献
1
Antimicrobial Agents That Inhibit the Outer Membrane Assembly Machines of Gram-Negative Bacteria.
J Microbiol Biotechnol. 2019 Jan 28;29(1):1-10. doi: 10.4014/jmb.1804.03051.
2
A 4.5-Year Within-Patient Evolution of a Colistin-Resistant Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Sequence Type 258.
Clin Infect Dis. 2018 Oct 15;67(9):1388-1394. doi: 10.1093/cid/ciy293.
3
Role of association of OmpK35 and OmpK36 alteration and bla and/or bla genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae.
Int J Antimicrob Agents. 2018 Dec;52(6):898-905. doi: 10.1016/j.ijantimicag.2018.03.020. Epub 2018 Apr 2.
4
Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
Ann Clin Microbiol Antimicrob. 2018 Mar 23;17(1):13. doi: 10.1186/s12941-018-0267-8.
5
Clonal emergence of Klebsiella pneumoniae ST14 co-producing OXA-48-type and NDM carbapenemases with high rate of colistin resistance in Dubai, United Arab Emirates.
Int J Antimicrob Agents. 2018 Jul;52(1):90-95. doi: 10.1016/j.ijantimicag.2018.03.003. Epub 2018 Mar 9.
6
Uropathogenic Escherichia coli virulence factor hemolysin A causes programmed cell necrosis by altering mitochondrial dynamics.
FASEB J. 2018 Aug;32(8):4107-4120. doi: 10.1096/fj.201700768R. Epub 2018 Feb 28.
7
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.
8
Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria.
Lancet Infect Dis. 2018 Apr;18(4):358-360. doi: 10.1016/S1473-3099(18)30112-9. Epub 2018 Feb 16.
9
Identification of a KPC-9-producing Klebsiella pneumoniae ST258 cluster among KPC-2-producing isolates of an ongoing outbreak in Northwestern Greece: a retrospective study.
Clin Microbiol Infect. 2018 May;24(5):558-560. doi: 10.1016/j.cmi.2017.12.007. Epub 2017 Dec 21.
10
Fosfomycin: Pharmacological, Clinical and Future Perspectives.
Antibiotics (Basel). 2017 Oct 31;6(4):24. doi: 10.3390/antibiotics6040024.
Zotero 插件